↑ 疾患リストへ ← 戻る

 309. 進行性ミオクローヌスてんかん [臨床試験数:4,薬物数:10(DrugBank:3),標的遺伝子数:4,標的パスウェイ数:4] 

Searched query = "Progressive myoclonus epilepsy", "Unverricht-Lundborg disease", "Lafora disease", "Benign adult familial myoclonus epilepsy", "BAFME"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 11/20/2019, 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Search in Page    e.g. "Phase 3", "Not recruiting", "Japan"    Synonyms (DrugBank) were also searched for.
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03351569December 9, 201516 December 2017Intravenous Immunoglobulin for Unverricht-Lundborg Disease.Intravenous Immunoglobulin for Unverricht-Lundborg Disease: Single-patient Trial.Unverricht-Lundborg DiseaseDrug: Intravenous immunoglobulinAzienda Socio Sanitaria Territoriale di MantovaNot recruiting18 Years25 YearsMale1Phase 3
2EUCTR2007-003210-33-FI03/08/200719 March 2012Effect of ropinirole hydrochloride in progressive myoclonic epilepsy of Unverricht–Lundborg typeEffect of ropinirole hydrochloride in progressive myoclonic epilepsy of Unverricht–Lundborg typeProgressive myoclonus epilepsy of the Unverricht–Lundborg disease (ULD) type
MedDRA version: 9.1 Level: PT Classification code 10054895 Term: Baltic myoclonic epilepsy
Trade Name: Requip
Product Name: Ropinirole hydrochloride
Pharmaceutical Form: Tablet
CAS Number: 91374208
Other descriptive name: ROPINIROLE HYDROCHLORIDE
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use
Department of Neurology, Turku University HospitalAuthorisedFemale: yes
Male: yes
15Finland
3NCT00357669November 200625 May 2015Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease in Adolescents and AdultsA Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Efficacy and Safety of Brivaracetam Used as Adjunctive Treatment for 12 Weeks in Adolescent and Adult Patients (=16 Years) With Genetically Ascertained Unverricht-Lundborg DiseaseUnverricht-Lundborg DiseaseDrug: Brivaracetam 25 mg;Drug: Brivaracetam 50 mg;Other: PlaceboUCB Pharma SANot recruiting16 YearsN/ABoth50Phase 3Finland;France;Italy;Netherlands;Réunion;Sweden;Tunisia
4NCT00368251November 200616 December 2017Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease (ULD) in Adolescents and AdultsA Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Efficacy and Safety of Brivaracetam Used as Adjunctive Treatment for 12 Weeks in Adolescent and Adult Patients (= 16 Years) With Genetically Ascertained Unverricht-Lundborg DiseaseUnverricht-Lundborg DiseaseOther: Placebo;Drug: BRV 2.5 mg;Drug: BRV 25 mg;Drug: BRV 50 mgUCB PharmaNot recruiting16 YearsN/AAll56Phase 3United States;Canada;Finland;France;Israel;Russian Federation;Serbia;Tunisia;Former Serbia and Montenegro